Quick Answer
Cytek Biosciences, Inc. reported R&D Expense of $36.47 million for fiscal year 2025.
Cytek Biosciences, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $36.47M | -7.4% |
| 2024 | $39.40M | -10.8% |
| 2023 | $44.15M | +26.7% |
| 2022 | $34.86M | +42.6% |
| 2021 | $24.44M | +78.5% |
| 2020 | $13.69M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $8.96M | -9.4% | +1.5% |
| June 30, 2025 | $8.83M | -11.7% | -9.2% |
| March 31, 2025 | $9.72M | -0.7% | -1.6% |
| September 30, 2024 | $9.88M | -11.5% | -1.2% |
| June 30, 2024 | $10.00M | -17.6% | +2.1% |
| March 31, 2024 | $9.80M | -1.8% | -12.3% |
| September 30, 2023 | $11.17M | +29.1% | -8.0% |
| June 30, 2023 | $12.14M | +43.9% | +21.7% |
- Cytek Biosciences, Inc. showed a decrease of -7.4% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Cytek Biosciences, Inc.’s r&d expense has grown by 166.3% (from $13.69 million to $36.47 million).
- The most recent figure is from Cytek Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: